Research ExplorerPublicationsRecent molecular discoveries in angiogenesis and antiangioge...

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer

Standard

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. / Welti, Jonathan; Loges, Sonja; Dimmeler, Stefanie; Carmeliet, Peter.

In: J CLIN INVEST, Vol. 123, No. 8, 01.08.2013, p. 3190-200.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Welti, J, Loges, S, Dimmeler, S & Carmeliet, P 2013, 'Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer', J CLIN INVEST, vol. 123, no. 8, pp. 3190-200. https://doi.org/10.1172/JCI70212

APA

Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J CLIN INVEST, 123(8), 3190-200. https://doi.org/10.1172/JCI70212

Vancouver

Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J CLIN INVEST. 2013 Aug 1;123(8):3190-200. https://doi.org/10.1172/JCI70212

Bibtex

@article{c20124342257448caab6824393ee7cf6,
title = "Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer",
abstract = "Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, and resistance. Here, we examine recent discoveries of new mechanisms underlying angiogenesis, discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangiogenic paradigms.",
keywords = "Angiogenesis Inhibitors, Angiogenic Proteins, Animals, Cell Proliferation, Chemotaxis, Endothelial Cells, Humans, Molecular Targeted Therapy, Neoplasms, Neovascularization, Pathologic, Vascular Endothelial Growth Factor Receptor-3",
author = "Jonathan Welti and Sonja Loges and Stefanie Dimmeler and Peter Carmeliet",
year = "2013",
month = aug,
day = "1",
doi = "10.1172/JCI70212",
language = "English",
volume = "123",
pages = "3190--200",
journal = "J CLIN INVEST",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

RIS

TY - JOUR

T1 - Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer

AU - Welti, Jonathan

AU - Loges, Sonja

AU - Dimmeler, Stefanie

AU - Carmeliet, Peter

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, and resistance. Here, we examine recent discoveries of new mechanisms underlying angiogenesis, discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangiogenic paradigms.

AB - Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, and resistance. Here, we examine recent discoveries of new mechanisms underlying angiogenesis, discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangiogenic paradigms.

KW - Angiogenesis Inhibitors

KW - Angiogenic Proteins

KW - Animals

KW - Cell Proliferation

KW - Chemotaxis

KW - Endothelial Cells

KW - Humans

KW - Molecular Targeted Therapy

KW - Neoplasms

KW - Neovascularization, Pathologic

KW - Vascular Endothelial Growth Factor Receptor-3

U2 - 10.1172/JCI70212

DO - 10.1172/JCI70212

M3 - SCORING: Journal article

C2 - 23908119

VL - 123

SP - 3190

EP - 3200

JO - J CLIN INVEST

JF - J CLIN INVEST

SN - 0021-9738

IS - 8

ER -